Litcius/Paper detail

Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE): an open-label, phase 2a dose-finding study

Olga Salamero, Antonieta Molero, José Antonio Pérez‐Simón, Montserrat Arnán, Rosa Coll, Sara Garcia-Ávila, Evelyn Acuña‐Cruz, Isabel Cano, Tim C. P. Somervaille, S. Gutiérrez, María Isabel Arévalo, Jordi Xaus, Carlos Buesa, Ana Limón, Douglas V. Faller, Francesc Bosch, Pau Montesinos

2024The Lancet Haematology15 citationsDOIOpen Access PDF

Topics & Concepts

Myeloid leukaemiaAzacitidineAlice (programming language)MedicineOpen labelOpen label studyOncologyPediatricsInternal medicineComputer scienceAdverse effectChemistryDNA methylationGeneBiochemistryProgramming languageGene expressionAcute Myeloid Leukemia ResearchHistone Deacetylase Inhibitors ResearchEpigenetics and DNA Methylation
Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE): an open-label, phase 2a dose-finding study | Litcius